HAL (France)open access
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
1, CLL, MRD, 0, 2, Fixed duration treatment
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 288048
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.